查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837138

結核病檢測市場按檢測類型、最終用戶、技術、樣本類型、分銷管道和應用分類－2025-2032 年全球預測

Tuberculosis Testing Market by Test Type, End User, Technology, Sample Type, Distribution Channel, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年結核病檢測市場規模將成長至 38.2 億美元，複合年成長率為 6.10%。

主要市場統計數據
基準年2024年 23.8億美元
預計2025年 25.2億美元
預測年份：2032年 38.2億美元
複合年成長率（%） 6.10%

全面說明當前結核病診斷動態，整合臨床實務、技術途徑、供應考量和採購重點

本執行摘要綜合了跨臨床路徑的關鍵發展，這些發展影響結核病診斷實踐、技術應用和最終用戶的優先事項。它提供了對不斷發展的診斷方法、監管變化、分銷動態以及影響實驗室、醫院和診所的營運壓力的統一視圖。本文件特意強調了相關人員在供應鏈審查日益嚴格的情況下必須調整採購、臨床工作流程和創新藍圖的實際意義。

本概述文件基於最新的監管更新、供應鏈模式和臨床指南，為臨床領導者和商業策略制定者提供了清晰的決策背景。它根據檢測類型和技術區分了診斷方法，並闡明了樣本類型和最終用戶環境如何影響檢測的選擇和使用。最終，本介紹為後續的針對性建議和營運行動奠定了基礎，以幫助各機構在其結核病檢測策略中優先考慮韌性、診斷準確性和以患者為中心的可及性。

技術融合、檢測分散化以及臨床期望的變化如何改變整個醫療環境中的診斷和營運重點

由於分子技術的進步、液檢體檢測的創新以及加速的即時診斷 (POC) 解決方案（可縮短獲得結果的時間），結核病診斷領域正在發生重大變化。這些技術進步也伴隨著臨床期望的改變。臨床醫生越來越期望獲得快速、可操作的結果，以便指導即時治療決策和接觸者追蹤介入。因此，診斷開發正轉向兼顧靈敏度、操作簡便性和快速週轉的平台。

同時，診斷生態系統正在適應新的分發和存取模式，優先考慮分散式檢查。雖然參考實驗室仍然是複雜檢測的核心，但醫院和診所越來越尋求能夠融入常規工作流程的快速診斷平台。基於培養的方法不斷改進，而核酸擴增技術和免疫診斷技術也正在最佳化，以便在各種醫療環境中廣泛應用。這種轉變需要研發、監管事務和商業營運之間的策略合作，以確保新型診斷方法能夠滿足臨床和物流需求。

關稅主導的供應鏈調整和策略採購轉變重塑了診斷服務的採購行為、製造足跡和庫存彈性

美國將於2025年提高關稅，這嚴重擾亂了全球診斷供應鏈，尤其是對結核病檢測工作流程至關重要的組件和耗材。進口試劑、檢測試劑套件和特定設備的關稅增加了到岸成本，凸顯了採購敏捷性的重要性。直接結果是，實驗室和醫院的採購團隊審查了其供應商組合和合約條款，以減輕短期成本影響並保持檢測的連續性。

作為應對，許多組織擴大了在地採購策略，並加快了替代供應商的資格認證流程，以減少對受關稅影響的進口途徑的依賴。這種轉變促使他們重新審視庫存政策，並轉向對常用耗材（如核酸萃取試劑套件和培養基）進行策略性儲備。同時，製造商面臨重新評估其全球生產基地的壓力，需要優先考慮區域製造投資和外包製造外包，以避免關稅的影響。監管途徑和供應驗證成為關注的焦點，因為替代供應商和新本地化的生產線需要及時和嚴格的性能檢驗。總而言之，這些調整表明需要靈活的採購慣例、多樣化的供應商生態系統和綜合的監管計劃，以避免與關稅相關的中斷，同時保持診斷的可靠性和臨床的連續性。

透過整合細分框架，將測試模式、最終用戶需求、檢體物流和分銷管道連結起來，優先考慮臨床和商業策略

了解細分市場對於制定結核病診斷產品開發、商業化和臨床應用策略至關重要。在評估檢測類型時，相關人員必須區分培養檢測、免疫測定、分子診斷和快速診斷。其中，有一些重要的亞型，例如用於層析法檢測的液體培養、固體培養、ELISA、Western blot免疫檢測測定、線性探針檢測和PCR，以及用於快速診斷的色譜法和側向層析。這些細分市場會影響通量、技術技能要求以及與現有實驗室基礎設施的兼容性，因此指南在何處投資自動化和培訓以獲得最大的營運效益。

最終用戶細分進一步細化了優先級，因為診所、醫院和參考實驗室對週轉時間、批次和複雜性容忍度有不同的需求。跨基於培養的技術、免疫診斷、脂阿拉伯甘露聚醣檢測和核酸增幅檢查的技術細分為產品創新途徑和監管策略提供了框架，因為不同的技術面臨不同的驗證要求和臨床證據閾值值。血液、痰和尿液等檢體類型會影響檢體採集物流、生物安全通訊協定以及適合照護現場或集中檢測。分銷管道動態，例如診斷實驗室、醫院藥房和線上藥房模式，決定了採購週期和報銷接觸點。最後，活動性結核病和潛伏性結核病之間的應用細分需要不同的表現特徵和解釋框架。整合這些細分層可讓相關人員確定投資優先順序、定義臨床部署模型並使證據產生與最關鍵的設定和用例保持一致。

區域監管協調、基礎設施多樣性和公共衛生優先事項將如何推動全球不同的採用途徑和交付策略

區域動態既影響診斷技術的採用路徑，也影響供應商面臨的營運需求。在美洲，重點是整合實驗室網路，確保檢測核准的監管一致性，並將診斷技術納入更廣泛的公共衛生工作。這些優先事項正在影響採購時間表，以及與現有實驗室資訊系統相容的有效、可互通解決方案的需求。

在歐洲、中東和非洲，監管協調工作和多樣化的醫療保健資金籌措模式正在鼓勵在產品准入、培訓和上市後監測方面採取更細緻的方法。這些地區的相關人員通常會在集中式參考檢測能力與擴大分散式篩檢的舉措之間取得平衡。在亞太地區，快速的都市化、多樣化的實驗室篩檢以及積極的公共衛生篩檢項目，支持加速採用即時診斷和核酸擴增技術。區域製造能力和物流考量進一步影響部署策略，使得跨區域夥伴關係和在地化工作對於確保供應連續性和滿足多樣化臨床需求日益重要。

結合平台相容性、本地製造和綜合服務的競爭策略和夥伴關係模式將提高可靠性和採用率。

活躍於結核病診斷領域的公司正透過產品改進、策略聯盟和業務擴張等措施來應對不斷變化的臨床和供應鏈需求。成熟的診斷製造商持續投資於儀器和平台相容性、檢測廣度和服務模式，以降低醫院和實驗室客戶的整體擁有成本。同時，規模較小的創新企業正專注於增強其利基產品，例如改進的樣本製備工作流程、提高橫向流動靈敏度以及只需極少操作員培訓的承包照護現場解決方案。

診斷製造商、試劑製造商和物流供應商之間的合作日益普遍，整合產品將儀器、耗材和數位支援服務結合，從而提高了客戶維繫和績效可預測性。此外，各公司正優先考慮法規遵循和證據生成，以推動其在各個醫療保健系統中的採用。諸如本地製造夥伴關係、API 和試劑採購多元化以及對生命週期支援的承諾等策略性舉措，正成為供應商差異化的核心。對於採購和臨床相關人員，供應商的選擇標準如今已不再局限於分析性能，還包括供應鏈透明度、上市後支援能力以及在發生中斷時快速檢驗替代採購方案的能力。

診斷產業領導者應採取切實可行的優先行動，以加強供應鏈、加速替代方案的檢驗，並使證據生成與臨床狀況保持一致

產業領導者應優先建構具有韌性的供應鏈，將短期緩解措施與長期策略協調相結合。首先，透過多元化供應商組合和檢驗關鍵試劑和耗材的次要來源，降低依賴單一來源的風險。其次，加快資格和性能檢驗通訊協定，確保能夠及時引入替代供應商和本地生產線，避免不必要的延誤。這些營運措施應與加強合約保護和庫存策略相結合，以應對突發中斷。

從商業性和臨床角度來看，領導者應投資於針對特定終端使用者環境和樣本類型的證據生成，重點關注醫院、診所和參考實驗室的實際性能、工作流程整合和經濟影響。此外，與區域製造商和物流合作夥伴達成合作協議可以縮短前置作業時間並減輕關稅影響。最後，組織應加強連接臨床營運、監管、採購和供應鏈團隊的跨職能能力，以實現快速的情境規劃和緊急計畫執行。總而言之，這些建議將有助於結核病診斷運作的短期連續性和長期適應性。

我們透明、多方法的研究途徑結合了主要專家訪談、供應鏈映射和監管整合，以提供可操作和檢驗的見解

本分析背後的調查方法結合了多源資料三角測量、專家訪談和供應鏈映射，從而提供了可靠的洞見。主要的定性資訊是透過與臨床實驗室主任、醫院系統採購官員以及診斷公司高級研發和監管專家進行結構化訪談獲得的，有助於深入了解營運重點和檢驗障礙。這些洞見與同期的監管指南文件和同行評審文獻進行了交叉引用，以檢驗臨床性能預期和技術權衡。

此外，我們還進行了供應鏈圖譜繪製，以確定試劑、設備和物流的關鍵節點，並針對關稅和本地製造方案的影響進行情境評估。數據整合強調假設的可重複性和可追溯性，研究結果經過內部同行評審，以確保關於採購行為、技術採用和監管回應的推論與觀察到的實踐一致。此調查方法支持基於證據的可操作建議，同時保持資料來源及其來源的透明度。

整合策略重點和業務要務，以確保在不斷變化的技術和政策壓力下診斷的連續性、臨床準確性和可及性

摘要：結核病診斷領域正處於曲折點，技術進步、臨床預期變化以及貿易政策等外部壓力正在匯聚，重塑採購和部署選擇。相關人員若能積極調整產品策略，使其與最終用戶工作流程一致，實現供應鏈多元化，並投資於針對特定環境的客製化證據，將最有能力確保診斷的連續性並改善臨床結果。

展望未來，持續的成功將取決於營運的適應性，包括快速檢驗替代供應商、整合臨床適用的即時診斷解決方案以及協調監管和採購部門以避免不必要中斷的能力。透過實施本文概述的策略和戰術性建議，臨床網路和診斷服務提供者可以增強其韌性，同時繼續擴大及時且準確的結核病檢測服務。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 整合人工智慧的快速分子檢測平台為偏遠診所的多重抗藥性結核病檢測提供了決策支援。
  • 在社區推廣計畫中擴大潛伏性結核感染的照護現場免疫診斷檢測
  • 監管部門的核准和政府資金的增加加速了下一代基於 CRISPR 的結核病診斷測試的開發
  • 將智慧型手機顯微鏡與雲端基礎的數據分析結合，實現遠端結核病塗片檢測和監測
  • 擴展全自動樣本到答案核酸擴增平台可減少高負荷區域的周轉時間
  • 製藥公司和公共衛生機構合作擴大都市區貧民窟的大規模篩檢工作
  • 採用結合宿主免疫反應和病原體檢測的多重生物標記組來提高結核病診斷的準確性
  • 建立利用行動實驗室的分散式檢查網路，以應對偏遠地區的結核病疫情

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 結核病檢測市場（依檢測類型）

  • 文化測試
    • 液體培養
    • 固態培養
  • 免疫學檢測
    • 伊麗莎
    • 蛋白質印跡法
  • 分子檢測
    • 線探針分析
    • PCR
  • 快速診斷測試
    • 層析法
    • 橫向流動

9. 結核病檢測市場（以最終用戶分類）

  • 診所
  • 醫院
  • 參考實驗室

10. 結核病檢測市場（依技術）

  • 基於文化的技術
  • 免疫診斷
  • 脂阿拉伯甘露聚醣測定
  • 核酸增幅檢查

第 11 章結核病檢測市場（依樣本類型）

  • 血
  • 痰
  • 尿

12. 結核病檢測市場（依分銷管道）

  • 診斷實驗室
  • 醫院藥房
  • 網路藥局

第13章結核病檢測市場（依應用）

  • 活動性結核病
  • 潛伏性結核病

14. 結核病檢測市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 15 章結核病檢測市場（按群體）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國結核病檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Cepheid, Inc.
    • QIAGEN NV
    • Hain Lifescience GmbH
    • Roche Diagnostics International Ltd
    • Abbott Laboratories
    • Becton Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • bioMerieux SA
Product Code: MRR-03252A5F927A

The Tuberculosis Testing Market is projected to grow by USD 3.82 billion at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.38 billion
Estimated Year [2025] USD 2.52 billion
Forecast Year [2032] USD 3.82 billion
CAGR (%) 6.10%

Comprehensive orientation to current tuberculosis diagnostic dynamics integrating clinical practice, technology pathways, supply considerations, and procurement priorities

This executive summary synthesizes critical developments shaping tuberculosis diagnostic practices, technology adoption, and end-user priorities across clinical pathways. It provides an integrated view of diagnostic modalities, regulatory shifts, distribution dynamics, and evolving operational pressures affecting laboratories, hospitals, and clinics. The narrative purposefully emphasizes practical implications for stakeholders who must align procurement, clinical workflows, and innovation roadmaps under intensified supply chain scrutiny.

By grounding the analysis in recent regulatory updates, supply chain patterns, and clinical guidance, this overview equips clinical leaders and commercial strategists with clear context for decision-making. It distinguishes between diagnostic approaches by test type and technology, and it clarifies how sample type and end-user settings influence test selection and utilization. Ultimately, the introduction sets a foundation for targeted recommendations and operational actions that follow, enabling organizations to prioritize resilience, diagnostic accuracy, and patient-centered access in their tuberculosis testing strategies.

How technological convergence, decentralization of testing, and changing clinical expectations are reshaping diagnostics and operational priorities across care settings

The landscape for tuberculosis diagnostics is undergoing transformative shifts driven by advances in molecular techniques, fluid sample testing innovations, and the acceleration of point-of-care solutions that shorten time-to-result. These technical evolutions are accompanied by changing clinical expectations: clinicians increasingly expect rapid, actionable results that can guide immediate therapeutic decisions and contact tracing interventions. As a result, diagnostic development is moving toward platforms that balance sensitivity with operational simplicity and faster turnaround.

Concurrently, the diagnostic ecosystem is adapting to new distribution and access models that prioritize decentralized testing. Reference laboratories remain central for complex assays, while hospitals and clinics increasingly seek rapid diagnostic platforms that can be integrated into routine workflows. Technology convergence is also notable: culture-based approaches continue to be refined while nucleic acid amplification technologies and immunodiagnostic methods are being optimized for broader use across diverse care settings. These shifts demand strategic alignment across R&D, regulatory affairs, and commercial operations to ensure that novel diagnostics meet both clinical and logistical requirements.

Tariff-driven supply chain adaptations and strategic sourcing shifts that reshaped procurement behavior, manufacturing footprints, and inventory resilience in diagnostic services

The introduction of enhanced United States tariff measures in 2025 created material perturbations across global diagnostic supply chains, particularly for components and consumables critical to tuberculosis testing workflows. Tariffs on imported reagents, assay kits, and select instrumentation increased landed costs and amplified the importance of procurement agility. As a direct consequence, laboratories and hospital procurement teams revisited supplier portfolios and contractual terms to mitigate near-term cost impacts and to preserve test continuity.

In response, many organizations expanded localized sourcing strategies and accelerated qualification processes for alternative suppliers to reduce dependence on tariff-affected import routes. This pivot prompted a re-examination of inventory policies and a shift toward strategic stockholding for high-use consumables such as nucleic acid extraction kits and culture media. At the same time, manufacturers faced pressure to reassess their global production footprints, with several prioritizing regional manufacturing investments or contract manufacturing arrangements to circumvent tariff exposure. Regulatory pathways and supply validations became focal points, since alternate suppliers and newly localized production lines required timely but rigorous performance verification. Taken together, these adjustments underscore the need for resilient procurement practices, diversified supplier ecosystems, and integrated regulatory planning to navigate tariff-driven disruptions while maintaining diagnostic reliability and clinical continuity.

Integrated segmentation framework linking test modalities, end-user needs, sample logistics, and distribution channels to prioritize clinical and commercial strategies

Understanding segmentation is essential to align product development, commercialization, and clinical adoption strategies across the tuberculosis diagnostic continuum. When evaluating test types, stakeholders must differentiate among culture tests, immunological assays, molecular diagnostics, and rapid diagnostic tests; within these, there are important subtypes such as liquid and solid culture methods, ELISA and Western blot immunoassays, line probe assays and PCR within molecular testing, and chromatographic and lateral flow techniques among rapid diagnostics. These distinctions affect throughput, technical skill requirements, and compatibility with existing laboratory infrastructure, and they therefore guide where investments in automation and training will deliver the greatest operational returns.

End-user segmentation further refines prioritization because clinics, hospitals, and reference laboratories have divergent needs for turnaround time, batch processing, and complexity tolerance. Technology segmentation-spanning culture-based techniques, immunodiagnostics, lipoarabinomannan assays, and nucleic acid amplification tests-frames the product innovation pathway and regulatory strategy, as different technologies face distinct validation demands and clinical evidence thresholds. Sample type considerations, including blood, sputum, and urine, influence specimen collection logistics, biosafety protocols, and the suitability of point-of-care versus centralized testing. Distribution channel dynamics such as diagnostic laboratories, hospital pharmacies, and online pharmacy models shape procurement cycles and reimbursement touchpoints. Finally, application segmentation between active and latent tuberculosis demands different performance characteristics and interpretive frameworks. By integrating these segmentation layers, stakeholders can prioritize investments, define go-to-clinic deployment models, and tailor evidence generation to the settings and use cases that matter most.

How regional regulatory harmonization, infrastructure variability, and public health priorities drive differentiated adoption pathways and supply strategies across global regions

Regional dynamics influence both the adoption pathway of diagnostic technologies and the operational imperatives that providers face. Across the Americas, there is strong emphasis on consolidating laboratory networks, ensuring regulatory alignment for assay approvals, and integrating diagnostics into broader public health initiatives. These priorities shape procurement timelines and the demand for validated, interoperable solutions compatible with existing laboratory information systems.

In Europe, the Middle East & Africa, regulatory harmonization efforts and varying healthcare financing models prompt a more nuanced approach to product entry, training, and post-market surveillance. Stakeholders in these regions often balance centralized reference testing capabilities with initiatives to expand decentralized screening. Across Asia-Pacific, rapid urbanization, varied laboratory infrastructure, and aggressive public health screening programs support accelerated adoption of point-of-care and nucleic acid amplification technologies. Regional manufacturing capacity and logistics considerations further influence deployment strategies, so cross-regional partnerships and localization efforts are increasingly important to ensure continuity of supply and to meet diverse clinical needs.

Competitive strategies and partnership models that combine platform compatibility, localized production, and integrated services to strengthen reliability and adoption

Companies active in tuberculosis diagnostics are pursuing a mix of product refinement, strategic partnerships, and operational expansion to address evolving clinical and supply chain demands. Established diagnostic manufacturers continue to invest in instrument-platform compatibility, assay breadth, and service models that reduce total cost of ownership for hospital and laboratory customers. At the same time, smaller innovators are focusing on niche product enhancements, including improved sample preparation workflows, lateral flow sensitivity gains, and turnkey point-of-care solutions that require minimal operator training.

Collaborations between diagnostics firms, reagent suppliers, and logistics providers are increasingly common, as integrated offers combining instrumentation, consumables, and digital support services improve customer retention and performance predictability. Moreover, companies are emphasizing regulatory readiness and evidence generation to facilitate adoption across diverse healthcare systems. Strategic moves such as localized manufacturing partnerships, API and reagent sourcing diversification, and lifecycle support commitments are central to vendor differentiation. For procurement and clinical stakeholders, vendor selection criteria now extend beyond analytical performance to include supply chain transparency, post-market support capabilities, and the ability to rapidly validate alternative sourcing options when disruptions occur.

Practical and prioritized actions for diagnostics leaders to harden supply chains, accelerate validation of alternatives, and align evidence generation with care settings

Industry leaders should prioritize building resilient supply chains that combine near-term mitigation with long-term strategic alignment. First, diversify supplier portfolios and validate secondary sources for critical reagents and consumables to reduce single-source exposure. Second, accelerate qualification and performance verification protocols so that alternate suppliers and localized production lines can be onboarded without unnecessary delay. These operational moves should be paired with enhanced contractual protections and inventory strategies to cushion against episodic disruptions.

From a commercial and clinical perspective, leaders should invest in evidence generation targeted to specific end-user settings and sample types, focusing on real-world performance, workflow integration, and economic implications within hospitals, clinics, and reference laboratories. Additionally, pursuing collaborative agreements with regional manufacturers and logistics partners can shorten lead times and reduce tariff sensitivity. Finally, organizations should strengthen cross-functional capabilities-linking clinical affairs, regulatory, procurement, and supply chain teams-to enable rapid scenario planning and implementation of contingency actions. Taken together, these recommendations support both short-term continuity and long-term adaptability in tuberculosis diagnostic operations.

Transparent multi-method research approach combining primary expert interviews, supply chain mapping, and regulatory synthesis to deliver actionable and verifiable insights

The research approach underpinning this analysis combined multi-source data triangulation, expert interviews, and supply chain mapping to ensure robust insights. Primary qualitative inputs were obtained through structured interviews with clinical laboratory directors, procurement leads in hospital systems, and senior R&D and regulatory professionals within diagnostic firms, enabling a grounded understanding of operational priorities and validation hurdles. These insights were cross-referenced with contemporaneous regulatory guidance documents and peer-reviewed literature to validate clinical performance expectations and technology trade-offs.

Additionally, supply chain mapping exercises identified critical nodes for reagents, instrumentation, and logistics, which informed scenario assessments around tariff impacts and localized manufacturing options. Data synthesis emphasized reproducibility and traceability of assumptions, and findings were subjected to internal peer review to ensure that inferences about procurement behavior, technology adoption, and regulatory readiness were consistent with observed practices. This methodology supports actionable, evidence-based recommendations while maintaining transparency in data sources and analytic steps.

Synthesis of strategic priorities and operational imperatives to secure diagnostic continuity, clinical accuracy, and access amid evolving technological and policy pressures

In summary, the tuberculosis diagnostic environment is at an inflection point where technological progress, shifting clinical expectations, and external pressures such as trade policy converge to reshape procurement and deployment choices. Stakeholders who proactively align product strategies with end-user workflows, diversify supply chains, and invest in evidence tailored to specific settings will be best positioned to ensure diagnostic continuity and to improve clinical outcomes.

Looking ahead, durable success will depend on operational adaptability: the ability to validate alternate suppliers quickly, to integrate point-of-care solutions where clinically appropriate, and to coordinate across regulatory and procurement functions to avoid unnecessary disruption. By implementing the strategic and tactical recommendations outlined herein, clinical networks and diagnostic providers can strengthen resilience while continuing to expand access to timely and accurate tuberculosis testing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid molecular testing platforms integrated with AI enabled decision support for multi drug resistant TB detection in remote clinics
  • 5.2. Expansion of point of care immunodiagnostic assays targeting latent tuberculosis infection detection in community outreach programs
  • 5.3. Increased regulatory approvals and government funding incentives accelerating development of next generation CRISPR based TB diagnostic tests
  • 5.4. Integration of smartphone microscopy and cloud based data analytics for remote tuberculosis smear examination and monitoring
  • 5.5. Scaling of fully automated sample to answer nucleic acid amplification platforms to reduce turnaround time in high burden regions
  • 5.6. Collaboration between pharmaceutical companies and public health agencies to expand mass screening initiatives in urban slums
  • 5.7. Adoption of multiplexed biomarker panels combining host immune response and pathogen detection for improved TB diagnosis accuracy
  • 5.8. Implementation of decentralized testing networks utilizing mobile laboratories to address TB outbreaks in remote communities

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Tuberculosis Testing Market, by Test Type

  • 8.1. Culture Test
    • 8.1.1. Liquid Culture
    • 8.1.2. Solid Culture
  • 8.2. Immunological Test
    • 8.2.1. Elisa
    • 8.2.2. Western Blot
  • 8.3. Molecular Test
    • 8.3.1. Line Probe Assay
    • 8.3.2. Pcr
  • 8.4. Rapid Diagnostic Test
    • 8.4.1. Chromatographic
    • 8.4.2. Lateral Flow

9. Tuberculosis Testing Market, by End User

  • 9.1. Clinics
  • 9.2. Hospitals
  • 9.3. Reference Laboratory

10. Tuberculosis Testing Market, by Technology

  • 10.1. Culture Based Technology
  • 10.2. Immunodiagnostic
  • 10.3. Lipoarabinomannan Assay
  • 10.4. Nucleic Acid Amplification Test

11. Tuberculosis Testing Market, by Sample Type

  • 11.1. Blood
  • 11.2. Sputum
  • 11.3. Urine

12. Tuberculosis Testing Market, by Distribution Channel

  • 12.1. Diagnostic Laboratory
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy

13. Tuberculosis Testing Market, by Application

  • 13.1. Active Tuberculosis
  • 13.2. Latent Tuberculosis

14. Tuberculosis Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Tuberculosis Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Tuberculosis Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Cepheid, Inc.
    • 17.3.2. QIAGEN N.V.
    • 17.3.3. Hain Lifescience GmbH
    • 17.3.4. Roche Diagnostics International Ltd
    • 17.3.5. Abbott Laboratories
    • 17.3.6. Becton Dickinson and Company
    • 17.3.7. Bio-Rad Laboratories, Inc.
    • 17.3.8. Thermo Fisher Scientific Inc.
    • 17.3.9. Siemens Healthineers AG
    • 17.3.10. bioMerieux SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. TUBERCULOSIS TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. TUBERCULOSIS TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TUBERCULOSIS TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIQUID CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIQUID CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIQUID CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIQUID CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIQUID CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIQUID CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SOLID CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SOLID CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SOLID CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SOLID CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SOLID CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SOLID CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY WESTERN BLOT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LINE PROBE ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LINE PROBE ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LINE PROBE ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LINE PROBE ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LINE PROBE ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LINE PROBE ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CHROMATOGRAPHIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CHROMATOGRAPHIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CHROMATOGRAPHIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CHROMATOGRAPHIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CHROMATOGRAPHIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CHROMATOGRAPHIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATERAL FLOW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATERAL FLOW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE BASED TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE BASED TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE BASED TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE BASED TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE BASED TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE BASED TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNODIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNODIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNODIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNODIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNODIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNODIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIPOARABINOMANNAN ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIPOARABINOMANNAN ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIPOARABINOMANNAN ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIPOARABINOMANNAN ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIPOARABINOMANNAN ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIPOARABINOMANNAN ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SPUTUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SPUTUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SPUTUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SPUTUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TUBERCULOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TUBERCULOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TUBERCULOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TUBERCULOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TUBERCULOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TUBERCULOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TUBERCULOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TUBERCULOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TUBERCULOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TUBERCULOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TUBERCULOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TUBERCULOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST TUBERCULOSIS TESTIN